Kellie Lucken
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kellie Lucken has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Andrew M. Fry
University of Leicester
14 shared publications - Laura O'REgan
School of Biochemistry, University of Bristol
14 shared publications - Sarah L. Pashley
School of Life Sciences, University of Nottingham
13 shared publications - Jene Choi
Departments of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
12 shared publications Josephina Sampson
12 shared publications- Richard Bayliss
Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, LS2 9JT, UK
12 shared publications
Latest Publications
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity
EML4-ALK V3 but not V1 localizes to microtubules during mitosis. A–D, H2228 and H3122 cells were grown on coverslips, stained with α-tubulin (red) and ALK (green) antibodies, and subjected to immunofluorescence microscopy analysis. DNA was stained with Hoechst 33258 (blue). Scale bars in metaphase, 5 μm, and in interphase, 10 μm. Colocalization of EML4-ALK with microtubules in interphase (A and B) and metaphase (C and D) was determined by measuring Pearson correlation coefficient along three 2 µm lines in 10 cells. ****, P < 0.0001 compared with H3122 cells by unpaired T test. E–H, Beas-2B cells expressing either HA-EML4-ALK V3 or V1 were induced for 48 hours and stained with HA (green) and α-tubulin (red) antibodies. DNA was stained with Hoechst 33258 (blue). Colocalization of EML4-ALK with microtubules in interphase (E and F) and metaphase (G and H) was determined by measuring Pearson correlation coefficient along three 2 µm lines in 10 cells. ****, P < 0.0001 and ***, P < 0.001 compared with HA-V1 cells by unpaired T test. Scale bars in metaphase, 5 μm, and in interphase, 10 μm. The three different shapes and colours in the dot plots in B, D, F, and H indicate data from three independent experiments, with large shapes referring to means and small shapes the individual data points. I and J, SRRF image reconstruction of EML4-ALK V3 (green) microtubules (red) in an interphase and metaphase H2228 (I) and Beas-2B:HA-EML4-ALK V3 (J) cell stained as above. Data are means +SD for three independent experiments.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity
EML4-ALK V3 but not V1 localizes to microtubules during mitosis. A–D, H2228 and H3122 cells were grown on coverslips, stained with α-tubulin (red) and ALK (green) antibodies, and subjected to immunofluorescence microscopy analysis. DNA was stained with Hoechst 33258 (blue). Scale bars in metaphase, 5 μm, and in interphase, 10 μm. Colocalization of EML4-ALK with microtubules in interphase (A and B) and metaphase (C and D) was determined by measuring Pearson correlation coefficient along three 2 µm lines in 10 cells. ****, P < 0.0001 compared with H3122 cells by unpaired T test. E–H, Beas-2B cells expressing either HA-EML4-ALK V3 or V1 were induced for 48 hours and stained with HA (green) and α-tubulin (red) antibodies. DNA was stained with Hoechst 33258 (blue). Colocalization of EML4-ALK with microtubules in interphase (E and F) and metaphase (G and H) was determined by measuring Pearson correlation coefficient along three 2 µm lines in 10 cells. ****, P < 0.0001 and ***, P < 0.001 compared with HA-V1 cells by unpaired T test. Scale bars in metaphase, 5 μm, and in interphase, 10 μm. The three different shapes and colours in the dot plots in B, D, F, and H indicate data from three independent experiments, with large shapes referring to means and small shapes the individual data points. I and J, SRRF image reconstruction of EML4-ALK V3 (green) microtubules (red) in an interphase and metaphase H2228 (I) and Beas-2B:HA-EML4-ALK V3 (J) cell stained as above. Data are means +SD for three independent experiments.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity
Expression of EML4-ALK V3 increases microtubule stability in mitosis. A, H3122 and H2228 cells were incubated on ice for 15 minutes before being fixed and stained with α-tubulin (red) and CENP-A (green) antibodies. DNA was stained with Hoechst 33258 (blue). Scale bars, 5 μm. B, Fluorescence intensity (a.u., arbitrary units) of K-fibers measured across half-spindles from cells shown in A was quantified using ImageJ. *, P < 0.05 compared with H3122 by unpaired T test. C, Beas-2B parental and HA-EML4-ALK V3 cells were induced with doxycycline for 48 hours and incubated on ice for 15 minutes before being stained with α-tubulin (red) and CENP-A (green) antibodies. DNA was stained with Hoechst 33258 (blue). Scale bars, 5 μm. D, Fluorescence intensity of K-fibers from cells shown in C was measured as in B. *, P < 0.05 compared with parental by unpaired T test. The three different shapes and colours in the dot plots in B and D indicate data from three independent experiments, with large shapes referring to means and small shapes the individual data points. E, H2228 cells were either mock-depleted (siMock) or depleted of EML4-ALK using siALK.1 or siALK.2 and stained with α-tubulin (red) and γ-tubulin (green) antibodies. DNA was stained with Hoechst 33258 (blue). Scale bars, 5 μm. F, Spindle intensity measured across half-spindles from cells shown in E was quantified using ImageJ and normalized to the intensity observed in siMock treated cells. **, P < 0.01 compared with siMock by one-way ANOVA. G, H2228 cells were depleted as in E and stained with α-tubulin antibodies. H, Astral microtubule intensity from cells shown in G was quantified as in F. **, P < 0.01 compared with siMock by one-way ANOVA. Data are means + SD for three independent experiments. Scale bars, 5 μm.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity
Expression of EML4-ALK V3 increases microtubule stability in mitosis. A, H3122 and H2228 cells were incubated on ice for 15 minutes before being fixed and stained with α-tubulin (red) and CENP-A (green) antibodies. DNA was stained with Hoechst 33258 (blue). Scale bars, 5 μm. B, Fluorescence intensity (a.u., arbitrary units) of K-fibers measured across half-spindles from cells shown in A was quantified using ImageJ. *, P < 0.05 compared with H3122 by unpaired T test. C, Beas-2B parental and HA-EML4-ALK V3 cells were induced with doxycycline for 48 hours and incubated on ice for 15 minutes before being stained with α-tubulin (red) and CENP-A (green) antibodies. DNA was stained with Hoechst 33258 (blue). Scale bars, 5 μm. D, Fluorescence intensity of K-fibers from cells shown in C was measured as in B. *, P < 0.05 compared with parental by unpaired T test. The three different shapes and colours in the dot plots in B and D indicate data from three independent experiments, with large shapes referring to means and small shapes the individual data points. E, H2228 cells were either mock-depleted (siMock) or depleted of EML4-ALK using siALK.1 or siALK.2 and stained with α-tubulin (red) and γ-tubulin (green) antibodies. DNA was stained with Hoechst 33258 (blue). Scale bars, 5 μm. F, Spindle intensity measured across half-spindles from cells shown in E was quantified using ImageJ and normalized to the intensity observed in siMock treated cells. **, P < 0.01 compared with siMock by one-way ANOVA. G, H2228 cells were depleted as in E and stained with α-tubulin antibodies. H, Astral microtubule intensity from cells shown in G was quantified as in F. **, P < 0.01 compared with siMock by one-way ANOVA. Data are means + SD for three independent experiments. Scale bars, 5 μm.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity
EML4-ALK V3 expressing cells have compromised SAC activity. A, H3122 and H2228 cells were treated with 5 μmol/L paclitaxel for 0, 16, or 24 hours and cell-cycle distribution quantified by staining with propidium iodide and cell-cycle distribution measured using flow cytometry. B, The percentage of H3122 (gray bars) and H2228 (blue bars) cells in G2–M based on analyses performed in A is shown. *, P < 0.05 compared with H3122 by unpaired T test. C, Beas-2B parental (gray) and HA-EML4-ALK V1 (blue) and HA-V3 (red) cells were induced with doxycycline for 48 hours and treated with 0.5 μmol/L nocodazole or 5 μmol/L paclitaxel for 24 hours and the percentage of cells in G2–M quantified using flow cytometry. *, P < 0.05, **P < 0.01 compared with parental by one-way ANOVA. D, H3122 cells were treated with DMSO alone, 0.5 μmol/L nocodazole or 5 μmol/L paclitaxel for 16 hours and stained with BubR1 (green) antibodies and Hoechst 33258 (blue). Scale bars, 5 μm. E, BubR1 intensity at kinetochores was quantified from the images shown in D using ImageJ and presented as fold-change compared with DMSO alone. *, P < 0.05 and **, P < 0.01 compared with DMSO by one-way ANOVA. F and G, Analyses were performed as in D and E, except using H2228 cells. Scale bars, 5 μm. Data are means +SD for three independent experiments.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity
EML4-ALK V3 expressing cells have compromised SAC activity. A, H3122 and H2228 cells were treated with 5 μmol/L paclitaxel for 0, 16, or 24 hours and cell-cycle distribution quantified by staining with propidium iodide and cell-cycle distribution measured using flow cytometry. B, The percentage of H3122 (gray bars) and H2228 (blue bars) cells in G2–M based on analyses performed in A is shown. *, P < 0.05 compared with H3122 by unpaired T test. C, Beas-2B parental (gray) and HA-EML4-ALK V1 (blue) and HA-V3 (red) cells were induced with doxycycline for 48 hours and treated with 0.5 μmol/L nocodazole or 5 μmol/L paclitaxel for 24 hours and the percentage of cells in G2–M quantified using flow cytometry. *, P < 0.05, **P < 0.01 compared with parental by one-way ANOVA. D, H3122 cells were treated with DMSO alone, 0.5 μmol/L nocodazole or 5 μmol/L paclitaxel for 16 hours and stained with BubR1 (green) antibodies and Hoechst 33258 (blue). Scale bars, 5 μm. E, BubR1 intensity at kinetochores was quantified from the images shown in D using ImageJ and presented as fold-change compared with DMSO alone. *, P < 0.05 and **, P < 0.01 compared with DMSO by one-way ANOVA. F and G, Analyses were performed as in D and E, except using H2228 cells. Scale bars, 5 μm. Data are means +SD for three independent experiments.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity
SAC deficiencies in cells expressing EML4-ALK V3 are dependent on ALK activity. A, Beas-2B parental cells were either mock transfected or transfected with plasmids encoding YFP alone, YFP-EML4-ALK V3 WT (wild-type) or YFP-EML4-ALK V3 KD (kinase-dead) for 24 hours. They were then treated with either DMSO alone or 0.5 µmol/L nocodazole for 16 hours before being analysed by flow cytometry. The top row indicates how cells were gated for expression of YFP using green channel forward scatter with the gate set above the upper threshold of fluorescence in the mock-transfected cells. The middle and bottom rows indicate DNA content following treatment with DMSO or nocodazole, respectively, with the profile shown for the ungated mock-transfected cells but the gated cells for those transfected with the different plasmids. B, The percentage of cells in G2–M were determined following treatment described in A. *, P < 0.05 compared with DMSO by unpaired T-test. C, H2228 cells were treated with DMSO alone or 0.149 µmol/L TAE-684 and analysed by time-lapse imaging; images captured at the times indicated (minutes) are shown. D, Quantification of mitotic duration for cells treated as in C. ***, P < 0.001 compared with DMSO by unpaired T test. E, H2228 cells were either mock-depleted or depleted of EML4-ALK using siALK.1 or siALK.2 and analysed as in C. F, Quantification of mitotic duration for cells treated as in E. **, P < 0.01 and ***, P < 0.001 compared with siMock by one-way ANOVA. Data are means +SD for three independent experiments (indicated in different colours in D and F). The three different shapes and colors in the dot plots in D and F indicate data from three independent experiments, with large shapes referring to means and small shapes the individual data points. Scale bars, 20 μm.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity
SAC deficiencies in cells expressing EML4-ALK V3 are dependent on ALK activity. A, Beas-2B parental cells were either mock transfected or transfected with plasmids encoding YFP alone, YFP-EML4-ALK V3 WT (wild-type) or YFP-EML4-ALK V3 KD (kinase-dead) for 24 hours. They were then treated with either DMSO alone or 0.5 µmol/L nocodazole for 16 hours before being analysed by flow cytometry. The top row indicates how cells were gated for expression of YFP using green channel forward scatter with the gate set above the upper threshold of fluorescence in the mock-transfected cells. The middle and bottom rows indicate DNA content following treatment with DMSO or nocodazole, respectively, with the profile shown for the ungated mock-transfected cells but the gated cells for those transfected with the different plasmids. B, The percentage of cells in G2–M were determined following treatment described in A. *, P < 0.05 compared with DMSO by unpaired T-test. C, H2228 cells were treated with DMSO alone or 0.149 µmol/L TAE-684 and analysed by time-lapse imaging; images captured at the times indicated (minutes) are shown. D, Quantification of mitotic duration for cells treated as in C. ***, P < 0.001 compared with DMSO by unpaired T test. E, H2228 cells were either mock-depleted or depleted of EML4-ALK using siALK.1 or siALK.2 and analysed as in C. F, Quantification of mitotic duration for cells treated as in E. **, P < 0.01 and ***, P < 0.001 compared with siMock by one-way ANOVA. Data are means +SD for three independent experiments (indicated in different colours in D and F). The three different shapes and colors in the dot plots in D and F indicate data from three independent experiments, with large shapes referring to means and small shapes the individual data points. Scale bars, 20 μm.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 6 from EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity
Synergistic response of H3122 and H2228 cells following combination treatment with paclitaxel and ALK inhibitors. A, H3122 and H2228 cells were treated with either DMSO or 4.27 µmol/L paclitaxel for 24 hours and the percentage of cells undergoing apoptosis determined by Annexin-V-PI staining and flow cytometry. *, P < 0.05 compared with DMSO by unpaired T test. B, H3122 and H2228 cells were treated with DMSO alone or 4.27 µmol/L paclitaxel for 24 hours before being replated at low density and cultured for 2 weeks to allow colonies to form. Colonies were detected by crystal violet staining. C, The surviving fraction of cells was calculated from the clonogenic assays described in B. **, P < 0.01 compared with DMSO by unpaired T test. D and E, Cell viability was quantified using Alamar blue following combination treatment of paclitaxel and alectinib or ceritinib at 1:1 ratios over a range of concentrations (1, 10, 100, 1,000, 10,000 nmol/L) using alamar blue and computed as the fraction effected (Fa, % inhibition of cell viability) compared with DMSO treated controls. Compusyn was used to generate Fa%: CI graphs for H2228 (D) and H3122 (E). F, This schematic model illustrates how expression of EML4-ALK V3, which induces both mitotic defects and loss of SAC activity, may promote genome instability, cell survival, and tumor progression. Combination treatment with ALK inhibitors, which support SAC activity, and paclitaxel, which also induces mitotic errors, may lead to improved outcomes for patients with ALK-positive NSCLC.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity
Synergistic response of H3122 and H2228 cells following combination treatment with paclitaxel and ALK inhibitors. A, H3122 and H2228 cells were treated with either DMSO or 4.27 µmol/L paclitaxel for 24 hours and the percentage of cells undergoing apoptosis determined by Annexin-V-PI staining and flow cytometry. *, P < 0.05 compared with DMSO by unpaired T test. B, H3122 and H2228 cells were treated with DMSO alone or 4.27 µmol/L paclitaxel for 24 hours before being replated at low density and cultured for 2 weeks to allow colonies to form. Colonies were detected by crystal violet staining. C, The surviving fraction of cells was calculated from the clonogenic assays described in B. **, P < 0.01 compared with DMSO by unpaired T test. D and E, Cell viability was quantified using Alamar blue following combination treatment of paclitaxel and alectinib or ceritinib at 1:1 ratios over a range of concentrations (1, 10, 100, 1,000, 10,000 nmol/L) using alamar blue and computed as the fraction effected (Fa, % inhibition of cell viability) compared with DMSO treated controls. Compusyn was used to generate Fa%: CI graphs for H2228 (D) and H3122 (E). F, This schematic model illustrates how expression of EML4-ALK V3, which induces both mitotic defects and loss of SAC activity, may promote genome instability, cell survival, and tumor progression. Combination treatment with ALK inhibitors, which support SAC activity, and paclitaxel, which also induces mitotic errors, may lead to improved outcomes for patients with ALK-positive NSCLC.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity
Summary of CI values at Fa 0.5 for H3122 and H2228 combination treatments.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity
Summary of CI values at Fa 0.5 for H3122 and H2228 combination treatments.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity
H2228 (V3) cells have increased mitotic errors compared with H3122 (V1) cells. A, C, E and G, H3122 and H2228 cells were stained with α-tubulin (red) and γ-tubulin (green) antibodies. DNA was stained with Hoechst 33258 (blue). Scale bars in metaphase, 5 μm, and in interphase, 10 μm. B, Box plot showing the proportion of cells with multipolar spindles quantified from 100 mitotic cells in A. *, P < 0.05 compared with H3122 by unpaired T test. D, Box plot showing the proportion of cells with misaligned chromosomes quantified from 100 bipolar metaphase cells in C. **, P < 0.01 compared with H3122 by unpaired t test. F, Box plot showing the proportion of cells with lagging chromosomes quantified from 100 anaphase cells in E. *, P < 0.05 compared with H3122 by unpaired t test. H, Box plot showing the proportion of cells with micronuclei quantified from 100 interphase cells in G. *, P < 0.05 compared with H3122 by unpaired t test. Data are means +SD for three independent experiments.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity
H2228 (V3) cells have increased mitotic errors compared with H3122 (V1) cells. A, C, E and G, H3122 and H2228 cells were stained with α-tubulin (red) and γ-tubulin (green) antibodies. DNA was stained with Hoechst 33258 (blue). Scale bars in metaphase, 5 μm, and in interphase, 10 μm. B, Box plot showing the proportion of cells with multipolar spindles quantified from 100 mitotic cells in A. *, P < 0.05 compared with H3122 by unpaired T test. D, Box plot showing the proportion of cells with misaligned chromosomes quantified from 100 bipolar metaphase cells in C. **, P < 0.01 compared with H3122 by unpaired t test. F, Box plot showing the proportion of cells with lagging chromosomes quantified from 100 anaphase cells in E. *, P < 0.05 compared with H3122 by unpaired t test. H, Box plot showing the proportion of cells with micronuclei quantified from 100 interphase cells in G. *, P < 0.05 compared with H3122 by unpaired t test. Data are means +SD for three independent experiments.
- Open Access
- 15 May 2025
- Published by The Company of Biologists in Journal of Cell Science
- Vol. 138 (10)
Abnormal nucleoli architecture and aggregate formation in nucleophosmin mutated acute myeloid leukaemia
Mutations in the nucleophosmin (NPM1) gene represent the most common genetic alteration in acute myeloid leukaemia (AML) and result in mis-localisation of the mutated protein from a predominantly nucleolar localisation to a predominantly cytoplasmic distribution. Here, we use high resolution imaging to demonstrate that NPM1 is crucial for maintaining normal nucleoli architecture and specifically the integrity of the enigmatic nucleoli rim, the least understood nucleolar compartment. We demonstrate that cell lines and primary cells with NPM1 mutations from individuals with AML have aberrant nucleoli architecture; intriguingly this abnormal nucleolar phenotype is reversible. Using a surrogate for rRNA synthesis, we show that the aberrant phenotype is associated with differences in nucleolar function; specifically, activity of RNA polymerase I is increased in NPM1 mutated cells. Perinucleolar chromatin organisation is also markedly different in NPM1 mutant cells. Finally, we report the novel finding that NPM1 mutated protein forms distinct aggregates and characterise these for the first time. This work reveals how nucleolar organisation contributes to the molecular mechanisms underpinning NPM1-driven AML, revealing novel therapeutic vulnerabilities.
- 15 May 2025
- Published by The Company of Biologists in Journal of Cell Science
- Vol. 138 (10)
Open AccessAbnormal nucleoli architecture and aggregate formation in nucleophosmin mutated acute myeloid leukaemia
Mutations in the nucleophosmin (NPM1) gene represent the most common genetic alteration in acute myeloid leukaemia (AML) and result in mis-localisation of the mutated protein from a predominantly nucleolar localisation to a predominantly cytoplasmic distribution. Here, we use high resolution imaging to demonstrate that NPM1 is crucial for maintaining normal nucleoli architecture and specifically the integrity of the enigmatic nucleoli rim, the least understood nucleolar compartment. We demonstrate that cell lines and primary cells with NPM1 mutations from individuals with AML have aberrant nucleoli architecture; intriguingly this abnormal nucleolar phenotype is reversible. Using a surrogate for rRNA synthesis, we show that the aberrant phenotype is associated with differences in nucleolar function; specifically, activity of RNA polymerase I is increased in NPM1 mutated cells. Perinucleolar chromatin organisation is also markedly different in NPM1 mutant cells. Finally, we report the novel finding that NPM1 mutated protein forms distinct aggregates and characterise these for the first time. This work reveals how nucleolar organisation contributes to the molecular mechanisms underpinning NPM1-driven AML, revealing novel therapeutic vulnerabilities.
- Open Access
Nucleophosmin mutations lead to abnormal, but reversible, nucleoli architecture and aggregate formation – Implications for NPM1-targeting therapies in AML
Mutations in the NPM1 gene represent the most common (>30% of patients) genetic alteration in Acute Myeloid Leukaemia (AML) and results in the mis-localisation of the mutated NPM1 protein from a predominantly nucleolar localisation to a predominantly cytoplasmic distribution. Numerous studies of NPM1 mutated AML have focussed on the aberrant cytoplasmic localisation of the mutated protein but efforts to reverse this mis-localisation therapeutically have so far resulted in limited clinical benefit. More recently, attention has shifted towards the nucleus with studies showing that mutant NPM1 binds to specific chromatin regions, where it directly regulates oncogenic gene expression. Here, we use high resolution imaging to demonstrate that Nucleophosmin (NPM1) is critical for maintaining normal nucleoli architecture and specifically the integrity of the nucleoli rim. We report for the first time that NPM1 mutated cell lines and primary samples have aberrant nucleoli architecture and demonstrate that the abnormal nucleoli phenotype is reversible. We also report the novel finding that NPM1 mutated protein forms distinct aggregates in NPM1 mutated cells and characterise these for the first time. This work reveals how nucleolar organisation contributes to the molecular mechanisms underpinning NPM1 driven AML and reveals unexpected novel vulnerabilities to be exploited for therapeutic intervention.
Open AccessNucleophosmin mutations lead to abnormal, but reversible, nucleoli architecture and aggregate formation – Implications for NPM1-targeting therapies in AML
Mutations in the NPM1 gene represent the most common (>30% of patients) genetic alteration in Acute Myeloid Leukaemia (AML) and results in the mis-localisation of the mutated NPM1 protein from a predominantly nucleolar localisation to a predominantly cytoplasmic distribution. Numerous studies of NPM1 mutated AML have focussed on the aberrant cytoplasmic localisation of the mutated protein but efforts to reverse this mis-localisation therapeutically have so far resulted in limited clinical benefit. More recently, attention has shifted towards the nucleus with studies showing that mutant NPM1 binds to specific chromatin regions, where it directly regulates oncogenic gene expression. Here, we use high resolution imaging to demonstrate that Nucleophosmin (NPM1) is critical for maintaining normal nucleoli architecture and specifically the integrity of the nucleoli rim. We report for the first time that NPM1 mutated cell lines and primary samples have aberrant nucleoli architecture and demonstrate that the abnormal nucleoli phenotype is reversible. We also report the novel finding that NPM1 mutated protein forms distinct aggregates in NPM1 mutated cells and characterise these for the first time. This work reveals how nucleolar organisation contributes to the molecular mechanisms underpinning NPM1 driven AML and reveals unexpected novel vulnerabilities to be exploited for therapeutic intervention.
- Open Access
- 6 March 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (5) , 107144
The mesenchymal morphology of cells expressing the EML4–ALK V3 oncogene is dependent on phosphorylation of Eg5 by NEK7
- 6 March 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (5) , 107144
Open AccessThe mesenchymal morphology of cells expressing the EML4–ALK V3 oncogene is dependent on phosphorylation of Eg5 by NEK7